Stock comparison
Bristol-Myers Squibb
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BMY
Bristol-Myers Squibb
Market cap
$116.4B
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.9B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BMY | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 50C | 60C | HRMY |
| Benjamin Graham | 50C | 55C | HRMY |
| Philip Fisher | 39D | 69B | HRMY |
| Peter Lynch | 53C | 55C | HRMY |
| Joel Greenblatt | 27F | 22F | BMY |
| Charlie Munger | 47D | 57C | HRMY |
| Terry Smith | 44D | 61C | HRMY |
Side-by-side metrics
| Metric | BMY | HRMY |
|---|---|---|
| Market cap | $116.4B | $1.9B |
| P/E (TTM) | 16.0x | 11.9x |
| EV/EBIT | 11.9x | 6.6x |
| ROIC (TTM) | 13.55% | 13.9% |
| Gross margin | 68.75% | 77.16% |
| Net margin | 15.01% | 18.27% |
| Revenue CAGR 5y | 0.96% | 29.85% |
| EPS CAGR 5y | 2.37% | 46.45% |
| Debt / Equity | 2.2x | 0.3x |
| Dividend yield | 4.39% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMY leads on
- Dividend yield4.39%vs 0.0%+100%
- Market cap$116.4Bvs $1.9B+98%
HRMY leads on
- Revenue CAGR 5y29.85%vs 0.96%+97%
- EPS CAGR 5y46.45%vs 2.37%+95%
- Debt / Equity0.3xvs 2.2x+88%
- EV/EBIT6.6xvs 11.9x+44%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.